BridgeBio Pharma, Inc.
(NASDAQ : BBIO)

( )
BBIO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Generic
symbolcompany%chnglast%shortavg$volume
AGNAllergan plc
0.73%169.052.9%$402.15m
ZTSZoetis, Inc. Class A
0.82%128.461.9%$237.59m
TEVATeva Pharmaceutical Industries Limited Sponsored ADR
-0.29%6.882.0%$99.84m
MYLMylan N.V.
2.33%18.903.2%$93.35m
TXMDTherapeuticsMD, Inc.
-0.39%3.8524.9%$12.72m
RDYDr. Reddy's Laboratories Ltd. Sponsored ADR
0.08%37.322.0%$5.99m
TAROTaro Pharmaceutical Industries Ltd.
2.14%76.046.5%$3.73m
LFVNLifeVantage Corporation
-0.64%14.033.3%$1.54m
ABEOAbeona Therapeutics, Inc.
1.82%2.247.6%$1.40m
JAGXJaguar Animal Health, Inc.
-6.39%0.719.8%$0.98m
KINKindred Biosciences, Inc.
4.31%6.530.3%$0.81m
CPHIChina Pharma Holdings, Inc.
-4.20%0.250.1%$0.02m

Company Profile

BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.